Moderna
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157)
Merck and Moderna expand INTerpath clinical trial program to evaluate mRNA-4157 (V940) in combination with KEYTRUDA for early-stage non-small cell lung cancer, aiming to improve outcomes and offer more treatment options.
Related Clinical Trials:
How Moderna's Success is Shaping the Biotech Industry
Moderna's mRNA technology revolutionized vaccine development, setting new standards for speed and innovation in biotech. The company's rapid COVID-19 vaccine development has inspired broader therapeutic applications and reshaped business models, emphasizing independent growth and public-private partnerships. Moderna's success has boosted investor confidence and industry agility, driving advancements in mRNA and related technologies.
Drug Development Company Secures $6.5 Million (Seed)
Dash Bio raised $6.5 million in seed financing led by Freestyle Capital to accelerate drug development using AI, robotics, and integrated software, aiming to reduce the 12-year average time and billions in costs associated with bringing new drugs to market.
Novo Nordisk, Moderna, Otsuka, AstraZeneca and Daiichi Sankyo named in advertisements
The article discusses the importance of enabling JavaScript for optimal app performance.
FDA extends approval for Pfizer's RSV vaccine to include younger adults
Pfizer's Abrysvo, the first RSV vaccine approved for adults under 50, aims to reduce RSV-related hospitalizations in young adults with chronic conditions. Previously approved for older adults and pregnant individuals, Abrysvo's expanded approval is based on a phase 3 clinical trial showing safety and efficacy in high-risk populations.
Are Norovirus Vaccines on the Horizon?
Early-phase data on two norovirus vaccine candidates, an mRNA vaccine from Moderna (mRNA-1403) and an oral tablet, showed promising safety and immunogenicity results, with the mRNA vaccine moving to phase III trials.
Moderna's norovirus vaccine enters Phase III trials in the UK
A Phase III trial of Moderna's norovirus vaccine mRNA-1403 is launched in the UK, aiming to recruit 2,500 participants across 39 sites. This marks the first norovirus vaccine trial in the UK, targeting a highly contagious virus causing vomiting, diarrhoea, and stomach cramps. The trial is supported by the UK Health Security Agency and the National Institute of Health and Research.
Related Clinical Trials:
Pfizer's RSV vaccine cleared by FDA for use in some younger adults
FDA expands Pfizer's RSV vaccine Abrysvo approval to adults aged 18-59 at increased risk, making it the broadest indication for adults. CDC's slow uptake of RSV vaccines and narrow guidance may change with this expansion. GSK also received expanded approval for its RSV shot Arexvy in adults aged 50-59 at increased risk. FDA's decision based on Pfizer's MONeT trial data showing strong immune responses in at-risk adults.
Pfizer gets a leg up in RSV as FDA clears jab for all adults
Pfizer's RSV vaccine Abrysvo gets FDA approval for adults 18-59, extending its previous 60+ label. Despite broader indications, market impact may be limited as US CDC rolls back RSV immunization recommendations to older populations. Sales of Abrysvo, GSK's Arexvy, and Moderna's mResvia will be closely watched for the 2024-25 season.
Doctors trial world's first vaccine against vomiting bug norovirus
Doctors are trialling the world's first mRNA vaccine against norovirus, aiming to reduce health and economic burdens. The phase 3 trial, called Nova 301, will enroll 25,000 adults, focusing on those over 60, across several countries. The vaccine, based on mRNA technology, is expected to generate a strong immune response. If successful, a marketing application could be submitted in 2026, with further trials planned for teenagers and younger children.
© Copyright 2024. All Rights Reserved by MedPath